Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 8201 results

  1. Indicator advisory committee (IAC)

    We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...

  2. Past appeals and decisions

    Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic

  3. Resource impact of NICE guidance

    We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.

  4. Resource planner

    Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.

  5. Patient Access Schemes Liaison Unit

    The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient

  6. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Last updated
    1 May 2024
    View recommendations

    Sections for TA540

  7. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

    Technology appraisal guidance
    Published
    1 May 2024
    View recommendations

    Sections for TA967

  8. Notify a procedure

    Tell us about an interventional procedure you think should be assessed by NICE.

  9. Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)

    NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    30 April 2024

    Sections for TA969

  10. NICE syndication API

    Embed NICE content in your digital products and services with our syndication API

  11. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment (HTE18)

    Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD....

    Health technology evaluation
    Published
    30 April 2024
    View recommendations

    Sections for HTE18

  12. Technology appraisal guidance

    Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

  13. Our methods and processes (health technology evaluation manual)

    Our health technology evaluation manual covers: how we choose medicines and other health technologies to evaluate (topic selection) the steps and...

  14. Types of technology appraisal recommendation

    The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.

  15. Technology appraisal guidance

    Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS. Browse technology...